Functional connectivity alterations between default mode network and occipital cortex in patients with obsessive-compulsive disorder (OCD)

por Geffen, T., Smallwood, J., Finke, C., Sjoerds, Z., Schlagenhauf, F.
Publicado 2021

Neuronal autoantibodies associated with cognitive impairment in melanoma patients

por Bartels, F, Strönisch, T, Farmer, K, Rentzsch, K, Kiecker, F, Finke, C
Publicado 2019

Cognitive impact of neuronal antibodies: encephalitis and beyond

por Gibson, L. L., McKeever, A., Coutinho, E., Finke, C., Pollak, T. A.
Publicado 2020

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis

por Barraco, D, Lasho, T L, Gangat, N, Finke, C, Elala, Y C, Pardanani, A, Tefferi, A
Publicado 2016

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes

por Pardanani, A, Finke, C, Lasho, T L, Al-Kali, A, Begna, K H, Hanson, C A, Tefferi, A
Publicado 2012

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients

por Cerquozzi, S., Barraco, D., Lasho, T., Finke, C., Hanson, C. A., Ketterling, R. P., Pardanani, A., Gangat, N., Tefferi, A.
Publicado 2017

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

por Tefferi, A, Jimma, T, Sulai, N H, Lasho, T L, Finke, C M, Knudson, R A, McClure, R F, Pardanani, A
Publicado 2012

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

por Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A
Publicado 2016

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia

por Lasho, T L, Finke, C M, Zblewski, D, Patnaik, M, Ketterling, R P, Chen, D, Hanson, C A, Tefferi, A, Pardanani, A
Publicado 2015

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance

por Patnaik, M M, Zahid, M F, Lasho, T L, Finke, C, Ketterling, R L, Gangat, N, Robertson, K D, Hanson, C A, Tefferi, A
Publicado 2016

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML

por Laborde, R R, Patnaik, M M, Lasho, T L, Finke, C M, Hanson, C A, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A
Publicado 2013

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

por Barraco, D, Elala, Y C, Lasho, T L, Begna, K H, Gangat, N, Finke, C, Hanson, C A, Ketterling, R P, Pardanani, A, Tefferi, A
Publicado 2016

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

por Barraco, D, Elala, Y C, Lasho, T L, Begna, K H, Gangat, N, Finke, C, Hanson, C A, Ketterling, R P, Pardanani, A, Tefferi, A
Publicado 2016

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

por Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A
Publicado 2013

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

por Pardanani, A, Abdelrahman, R A, Finke, C, Lasho, T T, Begna, K H, Al-Kali, A, Hogan, W J, Litzow, M R, Hanson, C A, Ketterling, R P, Tefferi, A
Publicado 2015

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

por Patnaik, M M, Wassie, E A, Padron, E, Onida, F, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Ketterling, R P, Komrokji, R, Tefferi, A, Solary, E
Publicado 2015

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

por Patnaik, M M, Wassie, E A, Padron, E, Onida, F, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Ketterling, R P, Komrokji, R, Tefferi, A, Solary, E
Publicado 2015

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations...

por Patnaik, M M, Lasho, T L, Finke, C M, Gangat, N, Caramazza, D, Holtan, S G, Pardanani, A, Knudson, R A, Ketterling, R P, Chen, D, Hoyer, J D, Hanson, C A, Tefferi, A
Publicado 2010

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

por Tefferi, A, Lasho, T L, Abdel-Wahab, O, Guglielmelli, P, Patel, J, Caramazza, D, Pieri, L, Finke, C M, Kilpivaara, O, Wadleigh, M, Mai, M, McClure, R F, Gilliland, D G, Levine, R L, Pardanani, A, Vannucchi, A M
Publicado 2010